AAV Capsid Mutations for CD34+ Stem Cell Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in efficiently transducing quiescent non-dividing hematopoietic stem cells and safety concerns due to insertional oncogenesis, limiting the effectiveness of viral vectors for long-term gene expression in the hematopoietic system.
Innovation Solution
Development of novel adeno-associated virus (AAV) isolates with unique capsid sequences that enhance transduction efficiency and tropism for CD34+ hematopoietic stem cells, allowing for sustained gene expression and targeted delivery to specific tissues like the liver and joints, while minimizing genomic integration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional viral vectors are used for gene transfer, then gene delivery can be achieved, but transduction efficiency in quiescent non-dividing hematopoietic stem cells remains low
Solution Approach 1:
The patent modifies the capsid protein parameters of AAV vectors by incorporating mutations from novel AAV isolates (such as AAV9 and AAV-L1) to enhance transduction efficiency. Specific amino acid substitutions in the capsid structure alter cellular interaction properties, enabling improved penetration into quiescent HSCs while maintaining safety profiles.
Solution Approach 2:
The patent uses AAV capsid proteins as intermediaries to facilitate gene delivery into HSCs. By engineering these capsid proteins with specific mutations, the vectors can mediate efficient transduction of quiescent cells without requiring cell division, acting as a bridge between the therapeutic gene and the target cell population.
2Duration of action of stationary object
If viral vectors integrate into genome, then long-term gene expression can be achieved, but insertional oncogenesis safety concerns arise
Solution Approach 1:
The patent leverages the natural non-integrating behavior of AAV vectors, which was previously considered a limitation for long-term expression, and converts it into a safety advantage. By using self-complementary AAV constructs that maintain episomal persistence, the system achieves sustained gene expression without the harmful integration events that cause insertional oncogenesis.
Solution Approach 2:
The patent employs episomal AAV vectors that function as temporary, non-integrating gene delivery vehicles. These vectors provide sufficient duration of gene expression for therapeutic benefit while avoiding permanent genomic integration, effectively using short-living episomal elements instead of permanent integrating vectors.
3Ease of manufacture
If AAV2 capsid is used, then vector system is well-established, but transduction efficiency in CD34+ HSC is limited by viral uncoating and intracellular trafficking restrictions
Solution Approach 1:
The patent introduces specific amino acid substitutions in the AAV capsid protein sequence to alter uncoating and intracellular trafficking parameters. Mutations such as those found in AAV9 and AAV-L1 capsids modify the vector's interaction with cellular machinery, enabling more efficient release of the therapeutic genome and transport to the nucleus in CD34+ HSCs.
Solution Approach 2:
The patent creates composite capsid structures by combining elements from different AAV serotypes (AAV2 backbone with mutations from AAV9, AAV-L1, or other isolates). This composite approach retains the manufacturability of the AAV2 system while incorporating beneficial properties from other isolates to overcome transduction barriers in HSCs.
4Productivity
If novel AAV isolates with unique capsid sequences are developed, then transduction efficiency and tropism for CD34+ HSC is enhanced, but vector complexity increases
Solution Approach 1:
The patent segments the capsid protein development process by identifying and isolating specific functional domains and critical amino acid residues that determine tropism and transduction efficiency. By focusing modifications on specific segments of the capsid rather than redesigning the entire vector system, the approach manages complexity while achieving enhanced performance.
Solution Approach 2:
The patent develops universal capsid mutation patterns that can be applied across different AAV vector systems. The identified mutations from novel isolates serve as multi-functional improvements that enhance transduction efficiency, modify tropism, and improve uncoating properties across various therapeutic applications, reducing the need for application-specific vector redesign.
Data Source
AI summary
Novel adeno-associated virus (AAV) isolates in nucleotide and amino acid forms and uses thereof are provided. The isolates show tropism for certain target tissues, such as blood stem cells, liver, heart and joint tissue, and may be used to transduce stem cells for introduction of genes of interest into the target tissues. Discrete modified portions of the cap gene, VP1, VP2, and VP3, may be used alone or in combination in the present methods.